Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis

Teigen, Mette Maja B., Duffull, Stephen, Dang, Lily and Johnson, David W. (2006) Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. Journal of Clinical Pharmacology, 46 11: 1259-1267. doi:10.1177/0091270006292987

Author Teigen, Mette Maja B.
Duffull, Stephen
Dang, Lily
Johnson, David W.
Title Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis
Journal name Journal of Clinical Pharmacology   Check publisher's open access policy
ISSN 0091-2700
Publication date 2006-11
Sub-type Article (original research)
DOI 10.1177/0091270006292987
Open Access Status
Volume 46
Issue 11
Start page 1259
End page 1267
Total pages 9
Editor L. L. von Moltke
Place of publication Thousand Oaks, CA, United States
Publisher Sage Science Press
Collection year 2006
Language eng
Subject C1
730118 Organs, diseases and abnormal conditions not elsewhere classified
111502 Clinical Pharmacology and Therapeutics
Abstract The aim of this study was to evaluate dosing schedules of gentamicin in patients with end-stage renal disease and receiving hemodialysis. Forty-six patients were recruited who received gentamicin while on hemodialysis. Each patient provided approximately 4 blood samples at various times before and after dialysis for analysis of plasma gentamicin concentrations. A population pharmacokinetic model was constructed using NONMEM (version 5). The clearance of gentamicin during dialysis was 4.69 L/h and between dialysis was 0.453 L/h. The clearance between dialysis was best described by residual creatinine clearance (as calculated using the Cockcroft and Gault equation), which probably reflects both lean mass and residual clearance mechanisms. Simulation from the final population model showed that predialysis dosing has a higher probability of achieving target maximum concentration (C-max) concentrations (> 8 mg/L) within acceptable exposure limits (area under the concentration-time curve [AUC] values > 70 and < 120 mg.h/L per 24 hours) than postdialysis dosing.
Keyword Aminoglycosides
End-stage renal disease
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
2007 Higher Education Research Data Collection
School of Pharmacy Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 24 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 26 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 10:42:03 EST